Brief: FDA Grants Rafael Pharmaceuticals Orphan Drug Designation For CPI-613 For Treatment Of Soft Tissue Sarcoma
29/10/2020 14:09
Oct 29 (Reuters) - RAFAEL PHARMACEUTICALS:
* FDA GRANTS RAFAEL PHARMACEUTICALS ORPHAN DRUG DESIGNATION
FOR
CPI-613® (DEVIMISTAT) FOR TREATMENT OF SOFT TISSUE SARCOMA
Source text for Eikon: ID:nGNX7jlxs5
Further company coverage: RFL.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rafael Holdings
See all newsBrief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million